Jupiter Topco LLC Takes Position in Prestige Consumer Healthcare Inc. $PBH

Jupiter Topco LLC bought a new position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) in the second quarter, HoldingsChannel reports. The institutional investor bought 22,589 shares of the company’s stock, valued at approximately $1,068,000.

Several other hedge funds and other institutional investors have also modified their holdings of PBH. UMB Bank n.a. grew its stake in Prestige Consumer Healthcare by 110.1% in the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after buying an additional 219 shares during the last quarter. Barrow Hanley Mewhinney & Strauss LLC acquired a new stake in Prestige Consumer Healthcare during the second quarter worth approximately $30,000. Versant Capital Management Inc lifted its position in Prestige Consumer Healthcare by 47.9% during the second quarter. Versant Capital Management Inc now owns 726 shares of the company’s stock worth $34,000 after acquiring an additional 235 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Prestige Consumer Healthcare by 69.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock worth $35,000 after acquiring an additional 236 shares during the period. Finally, Danske Bank A S bought a new stake in shares of Prestige Consumer Healthcare during the third quarter worth approximately $37,000. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Stock Down 0.7%

Shares of PBH opened at $52.17 on Friday. Prestige Consumer Healthcare Inc. has a one year low of $42.62 and a one year high of $71.07. The company has a market cap of $2.47 billion, a P/E ratio of 14.61, a P/E/G ratio of 1.64 and a beta of 0.33. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.23 and a quick ratio of 1.99. The firm has a 50 day simple moving average of $50.76 and a two-hundred day simple moving average of $54.14.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, August 6th. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.89 by $0.09. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The firm had revenue of $265.71 million for the quarter, compared to the consensus estimate of $253.02 million. During the same quarter last year, the business posted $0.90 EPS. The company’s revenue was up 6.5% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.56 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on PBH. Canaccord Genuity Group lowered their target price on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Weiss Ratings downgraded Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Oppenheimer lowered Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Finally, Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research report on Monday, August 10th. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $70.75.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).